Cover Image
市場調查報告書

HMGB1 (High Mobility Group Protein Box-1):開發中產品分析

High Mobility Group Protein Box-1 (HMGB1) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 358693
出版日期 內容資訊 英文 40 Pages
訂單完成後即時交付
價格
Back to Top
HMGB1 (High Mobility Group Protein Box-1):開發中產品分析 High Mobility Group Protein Box-1 (HMGB1) - Pipeline Review, H1 2016
出版日期: 2016年04月30日 內容資訊: 英文 40 Pages
簡介

本報告提供全球各國治療HMGB1 (High Mobility Group Protein Box-1) 所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

  • 簡介
    • 分析範圍
  • HMGB1 (High Mobility Group Protein Box-1)的概要
  • 治療藥的開發
    • 臨床實驗中的產品:臨床實驗的各階段
    • 臨床實驗中的產品:各治療領域
    • 臨床實驗中的產品:不同症狀
  • 開發中產品的概要
    • 初期階段的產品
  • 各企業開發中的產品
  • 各大學/研究機關開發中的產品
  • 治療藥的評估
    • 單劑治療藥/並用治療藥的情況
    • 各作用機制
    • 各投藥途徑
    • 各分子類型
  • HMGB1開發治療藥的企業
    • Affibody AB
    • Bio3 Research S.r.l
    • Evec, Inc.
    • Ribomic Inc.
  • 藥物簡介
    • Antibodies to Antagonize HMGB-1 for Cardiovascular Diseases
      • 產品概要
      • 作用機制
      • 研究開發 (R&D)的進展
    • CTR-1
    • CTR-2
    • CTR-3
    • CTR-4
    • EV-007156
    • Monoclonal Antibody to Inhibit HMGB1 for Brain Infarction
    • RBM-005
    • Recombinant Protein for Oncology
    • Recombinant Protein to Inhibit HMGB1 for Stroke
  • 開發暫停的計劃
  • 值得注意的最新趨勢·新聞稿 (1件)
  • 附錄

圖表一覽

目錄
Product Code: GMDHC0012TDB

Summary

Global Markets Direct's, 'High Mobility Group Protein Box-1 (HMGB1) - Pipeline Review, H1 2016', provides in depth analysis on High Mobility Group Protein Box-1 (HMGB1) targeted pipeline therapeutics.

The report provides comprehensive information on the High Mobility Group Protein Box-1 (HMGB1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in High Mobility Group Protein Box-1 (HMGB1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for High Mobility Group Protein Box-1 (HMGB1)
  • The report reviews High Mobility Group Protein Box-1 (HMGB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in High Mobility Group Protein Box-1 (HMGB1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses High Mobility Group Protein Box-1 (HMGB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to High Mobility Group Protein Box-1 (HMGB1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for High Mobility Group Protein Box-1 (HMGB1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding High Mobility Group Protein Box-1 (HMGB1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • High Mobility Group Protein Box-1 (HMGB1) Overview
  • Therapeutics Development
    • High Mobility Group Protein Box-1 (HMGB1) - Products under Development by Stage of Development
    • High Mobility Group Protein Box-1 (HMGB1) - Products under Development by Therapy Area
    • High Mobility Group Protein Box-1 (HMGB1) - Products under Development by Indication
  • High Mobility Group Protein Box-1 (HMGB1) - Pipeline Products Glance
    • Early Stage Products
  • High Mobility Group Protein Box-1 (HMGB1) - Products under Development by Companies
  • High Mobility Group Protein Box-1 (HMGB1) - Products under Development by Universities/Institutes
  • High Mobility Group Protein Box-1 (HMGB1) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • High Mobility Group Protein Box-1 (HMGB1) - Companies Involved in Therapeutics Development
    • Affibody AB
    • Bio3 Research S.r.l
    • Evec, Inc.
    • Ribomic Inc.
  • High Mobility Group Protein Box-1 (HMGB1) - Drug Profiles
    • Antibodies to Antagonize HMGB-1 for Cardiovascular Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CTR-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CTR-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CTR-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CTR-4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EV-007156 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit HMGB1 for Brain Infarction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RBM-005 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Inhibit HMGB1 for Stroke - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • High Mobility Group Protein Box-1 (HMGB1) - Dormant Projects
  • High Mobility Group Protein Box-1 (HMGB1) - Featured News & Press Releases
    • Nov 16, 2012: Bio3 Research Receives Hong Kong Patent For HMGB1 Antibodies To Treat Vascular Diseases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Affibody AB, H1 2016
  • Pipeline by Bio3 Research S.r.l, H1 2016
  • Pipeline by Evec, Inc., H1 2016
  • Pipeline by Ribomic Inc., H1 2016
  • Dormant Projects, H1 2016
  • Dormant Projects (Contd..1), H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top